首页 » BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
https://ir.beigene.com/news-details/?id=65d92c44-3f6f-4a00-9433-52c144854bbc